|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/06/21 Achilles Therapeutics plc S-8 4/06/21 3:121K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: S-8 Registration Statement - Securities for an HTML 47K
Employee Benefit Plan
2: EX-5.1 Opinion of Counsel re: Legality HTML 36K
3: EX-23.1 Consent of Expert or Counsel HTML 5K
| EX-23.1 |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Achilles Therapeutics plc
We consent to the use of our report dated March 1, 2021, except for the effects of the share split discussed in Note 15 to the consolidated financial statements, as to which the date is March 29, 2021, with respect to the consolidated balance sheets of Achilles Therapeutics plc (and subsidiaries) as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, shareholders’ equity, and cashflows for each of the years in the two-year period ended December 31, 2020, and the related notes, incorporated herein by reference.
/s/ KPMG LLP
Reading, United Kingdom
| This ‘S-8’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / Effective on: | 4/6/21 | |||
| 3/29/21 | 8-A12B, CORRESP, F-1/A | |||
| 3/1/21 | DRS, DRS/A, F-1 | |||
| 12/31/20 | ||||
| 12/31/19 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/04/24 Achilles Therapeutics plc S-8 4/04/24 4:117K Donnelley … Solutions/FA 3/08/23 Achilles Therapeutics plc S-8 3/08/23 4:109K Donnelley … Solutions/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/25/21 Achilles Therapeutics plc F-1/A 4:6.4M Donnelley … Solutions/FA 3/01/21 Achilles Therapeutics plc F-1 16:9.3M Donnelley … Solutions/FA |